Drug intelligence / Profile preview

COH29

Development stage: Phase 1
Lead developer: City of Hope
Modality: Small Molecules
Administration: Oral

Overview

COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity. It works by binding to the ligand-binding pocket of the RNR M2 subunit (hRRM2) near the C-terminal tail, blocking the interaction between hRRM1 and hRRM2 subunits and interfering with the assembly of the active RNR complex. Developed at City of Hope Cancer Center, COH29 has shown efficacy against multiple cancer types in preclinical studies, particularly leukemia and ovarian cancer.

Other names: N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide

Targets

RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on COH29.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COH29.

Explore the full profile